|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-7-31
|
|
pubmed:abstractText |
Acarbose is an oral antidiabetic mainly acting on postprandial blood glucose, inhibiting alphaglucosidase. Through this mechanism, it could improve the peripheral insulin sensitivity and/or increase the insulin secretion. The aim of the present study is to assess the therapeutic efficacy of Acarbose in obese type 2 diabetic patients on both insulin resistance and insulin secretion.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1262-3636
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
195-200
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12149599-Acarbose,
pubmed-meshheading:12149599-Blood Glucose,
pubmed-meshheading:12149599-C-Peptide,
pubmed-meshheading:12149599-Cholesterol,
pubmed-meshheading:12149599-Diabetes Mellitus,
pubmed-meshheading:12149599-Diabetes Mellitus, Type 2,
pubmed-meshheading:12149599-Double-Blind Method,
pubmed-meshheading:12149599-Hemoglobin A, Glycosylated,
pubmed-meshheading:12149599-Humans,
pubmed-meshheading:12149599-Hypoglycemic Agents,
pubmed-meshheading:12149599-Insulin,
pubmed-meshheading:12149599-Insulin Resistance,
pubmed-meshheading:12149599-Obesity,
pubmed-meshheading:12149599-Placebos,
pubmed-meshheading:12149599-Research Design
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
|
|
pubmed:affiliation |
Division of Therapeutic Education for Chronic Diseases, University Hospital Geneva, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
